Immune responses towards bioengineered tissues and strategies to control them

Current Opinion in Organ Transplantation
Andrea AngelettiPaolo Cravedi

Abstract

Research into development of artificial tissues and bioengineered organs to replace physiological functions of injured counterparts has highlighted a previously underestimated challenge for its clinical translatability: the immune response against biomaterials. Herein, we will provide an update and review current knowledge regarding this important barrier to regenerative medicine. Although a clear understanding of the immune reactivity against biomaterials remains elusive, accumulating evidence indicates that innate immune cells, primarily neutrophils and macrophages, play a key role in the initial phases of the immune response. More recently, data have shown that in later phases, T and B cells are also involved. The use of physicochemical modifications of biomaterials and cell-based strategies to modulate the host inflammatory response is being actively investigated for effective biomaterial integration. The immune response towards biomaterials and bioengineered organs plays a crucial role in determining their utility as transplantable grafts. Expanding our understanding of these responses is necessary for developing protolerogenic strategies and delivering on the ultimate promise of regenerative medicine.

References

Dec 1, 1994·Journal of Leukocyte Biology·J A Smith
Feb 2, 2002·Experimental Hematology·Amelia BartholomewRonald Hoffman
May 16, 2002·The Journal of Biological Chemistry·Jayne LesleyRobert Hyman
Oct 16, 2002·Annals of the Rheumatic Diseases·M J López-ArmadaG Herrero-Beaumont
Oct 21, 2004·Blood·Sudeepta Aggarwal, Mark F Pittenger
Jul 22, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Felicita BaratelliSteven M Dubinett
Aug 16, 2005·Stem Cells·Panagiota A SotiropoulouMichael Papamichail
Sep 6, 2005·Blood·Anna CorcioneAntonio Uccelli
Sep 5, 2006·The Journal of Bone and Joint Surgery. American Volume·Ph HernigouH Rouard
Dec 18, 2007·Seminars in Immunology·Stephen F Badylak, Thomas W Gilbert
Dec 29, 2007·Seminars in Immunology·James M AndersonDavid T Chang
Jan 15, 2008·Seminars in Immunology·Kim S Jones
Dec 8, 2009·Science·Richard O Hynes
May 8, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·André MercanziniPhilippe Renaud
Jul 14, 2010·Trends in Immunology·Charlotte SummersEdwin R Chilvers
Apr 1, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Carlo Alberto RossiPaolo De Coppi
Apr 27, 2011·Proceedings of the National Academy of Sciences of the United States of America·Paul L BollykyGerald T Nepom
Jun 28, 2011·Tissue Engineering. Part a·Raymond L PageTanja Dominko
Jul 29, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Najib El HaddadReza Abdi
Sep 22, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Moïra FrançoisJacques Galipeau
Oct 13, 2011·BioTechniques·Ryan M BoehlerLonnie D Shea
Mar 20, 2012·Circulation Research·Oliver Soehnlein
Jul 27, 2012·Frontiers in Immunology·Marcella FranquesaJ M Grinyó
Oct 2, 2012·Journal of Biomolecular Screening·Marcie GlicksmanKelvin Lam

❮ Previous
Next ❯

Citations

Feb 16, 2020·Medicina·Andrea AngelettiGaetano La Manna

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Annual Review of Biomedical Engineering
Nathan A HotalingJulia E Babensee
BioMed Research International
Austin B GardnerAbhinav P Acharya
Nihon rinsho. Japanese journal of clinical medicine
Kou Imachi
© 2021 Meta ULC. All rights reserved